MiPLA Stats & Data

MiPLA was originally synthesized by Albert Hofmann at Sandoz Laboratories as part of the foundational structure-activity relationship research into LSD. Eli Lilly and Company subsequently filed a patent for the compound in 1956, with formal publication following in 1961. The compound underwent more detailed investigation during the 1990s by David E. Nichols and his research team at Purdue University. MiPLA has primarily served as a pharmacological research tool for elucidating the serotonergic mechanisms through which LSD produces its hallucinogenic effects, with particular focus on its binding characteristics at the 5-HT2A receptor. Alexander Shulgin also documented early human trials with the substance in his "Pharmacology Notes #9" and "Pharmacology Notes C," reporting that subjects experienced LSD-like psychedelic effects at doses suggesting a potency approximately two to three times lower than LSD. MiPLA first emerged on the recreational drug market as a novel designer drug around 2018.

The toxicity and long-term health effects of recreational MiPLA use has not been studied in any scientific context and the exact toxic dose is unknown. This is because MiPLA is a research chemical with very little history of human usage. The current body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. However, as is the case for LSD, it is possible that MiPLA can act as a potential trigger for those with underlying psychiatric conditions.

Effects aggregated from 7 experience reports (7 Erowid)

From 9 individual dose entries

Most common forms and preparations reported